Exelixis Inc. (EXEL)

21.16
0.18 0.88
NASDAQ : Health Technology
Prev Close 20.97
Open 21.17
Day Low/High 20.95 / 21.46
52 Wk Low/High 13.42 / 25.31
Volume 1.12M
Avg Volume 2.94M
Exchange NASDAQ
Shares Outstanding 301.77M
Market Cap 6.27B
EPS 2.30
P/E Ratio 9.99
Div & Yield N.A. (N.A)

Latest News

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

How I Use Options to Mitigate Risk and Create Income

How I Use Options to Mitigate Risk and Create Income

Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

These 'Small Ball' Names Will Outperform the Market in 2019

These 'Small Ball' Names Will Outperform the Market in 2019

Investors are already more focused on what lies ahead when Q1 results start in early April.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Synchrony, Exelixis Look Like Good Values

Synchrony, Exelixis Look Like Good Values

The credit card provider and the biotech concern appear cheap relative to their potential.

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

Exelixis Has an Enviable Chart Pattern

Exelixis Has an Enviable Chart Pattern

The $30 area is probably up next.

Fewer Oars Make Market Tough Row to Hoe

Fewer Oars Make Market Tough Row to Hoe

Investors should be more cautious heading into the summer.

These Stocks Are Changing Direction

These Stocks Are Changing Direction

Finding bullish and bearish reversals in the market.

Biotech Heating up on M&A Speculation

The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro  is not giving up its big takeover speculation rise yesterday and is up another 3%...

Hopes for Tax Reform, Less Regulation Lift Indices

Hopes for Tax Reform, Less Regulation Lift Indices

Technical indicators indicate the markets are not extended and have consolidated nicely.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Look at Silver Miners and Some Names That Have Pulled Back

Look at Silver Miners and Some Names That Have Pulled Back

I'm feeling pressure to force some trades today, but I'm trying to stay selective.